{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:11:09Z","timestamp":1791803469205,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.breast.2026.104812","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:14:42Z","timestamp":1778789682000},"page":"104812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Neurokinin pathway antagonists for vasomotor symptoms in women with breast cancer: focus on elinzanetant and fezolinetant"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-711X","authenticated-orcid":false,"given":"Katarzyna","family":"Pogoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Arecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.breast.2026.104812_bib1","doi-asserted-by":"crossref","first-page":"oyaf002","DOI":"10.1093\/oncolo\/oyaf002","article-title":"Management of vasomotor symptoms in cancer patients","volume":"30","author":"Zhu","year":"2025","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.breast.2026.104812_bib2","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.2105\/AJPH.2005.066936","article-title":"Longitudinal analysis of the association between vasomotor symptoms and race\/ethnicity across the menopausal transition: study of women's health across the nation","volume":"96","author":"Gold","year":"2006","journal-title":"Am J Public Health"},{"issue":"7","key":"10.1016\/j.breast.2026.104812_bib3","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1016\/S1470-2045(20)30666-5","article-title":"Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer","volume":"22","author":"Franzoi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104812_bib4","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1188\/02.ONF.E16-E25","article-title":"Hot flashes and related outcomes in breast cancer survivors and matched comparison women","volume":"29","author":"Carpenter","year":"2002","journal-title":"Oncol Nurs Forum"},{"issue":"4","key":"10.1016\/j.breast.2026.104812_bib5","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/13697137.2024.2340472","article-title":"Real-world clinical evaluation of natural and induced vasomotor symptoms in the USA and Europe","volume":"27","author":"Kingsberg","year":"2024","journal-title":"Climacteric"},{"issue":"6","key":"10.1016\/j.breast.2026.104812_bib6","doi-asserted-by":"crossref","first-page":"683","DOI":"10.6004\/jnccn.2021.7116","article-title":"Adjuvant hormone therapy-related hot flashes predict treatment discontinuation and worse breast cancer prognosis","volume":"20","author":"Zeng","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"16","key":"10.1016\/j.breast.2026.104812_bib7","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1200\/JCO.24.01131","article-title":"Explaining the relationships between age, endocrine therapy persistence, and risk of recurrence in hormone receptor-positive early breast cancer: a nationwide cohort study","volume":"43","author":"Dumas","year":"2025","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.breast.2026.104812_bib8","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1200\/JCO.2015.63.8619","article-title":"Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence","volume":"34","author":"Chirgwin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.breast.2026.104812_bib9","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.19.01758","article-title":"Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk","volume":"38","author":"Pistilli","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.breast.2026.104812_bib10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11864-024-01190-8","article-title":"Ovarian suppression: early menopause and late effects","volume":"25","author":"Molinelli","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104812_bib11","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.annonc.2025.09.007","article-title":"Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen international breast cancer consensus statement on individualizing therapy for patients with early breast cancer","volume":"36","author":"Burstein","year":"2025","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.breast.2026.104812_bib12","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.3390\/cancers16193267","article-title":"Menopausal hormone therapy in breast cancer survivors","volume":"16","author":"Culhane","year":"2024","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.breast.2026.104812_bib13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10549-021-06436-9","article-title":"Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis","volume":"191","author":"Poggio","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.breast.2026.104812_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.6118\/jmm.20000","article-title":"The 2020 menopausal hormone therapy guidelines","volume":"26","author":"Lee","year":"2020","journal-title":"J Menopausal Med"},{"issue":"7","key":"10.1016\/j.breast.2026.104812_bib16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American menopause society","volume":"29","author":"Faubion","year":"2022","journal-title":"Menopause"},{"issue":"11","key":"10.1016\/j.breast.2026.104812_bib17","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2022.07.007","article-title":"ESO\u2013ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)","volume":"33","author":"Paluch-Shimon","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.breast.2026.104812_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3949\/ccjm.91a.23067","article-title":"Nonhormone therapies for vasomotor symptom management","volume":"91","author":"Iyer","year":"2024","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.breast.2026.104812_bib19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40262-015-0315-x","article-title":"Augmentation of endoxifen exposure in tamoxifen-treated women following SSRI switch","volume":"55","author":"Binkhorst","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.breast.2026.104812_bib20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.yfrne.2013.07.003","article-title":"Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes","volume":"34","author":"Rance","year":"2013","journal-title":"Front Neuroendocrinol"},{"issue":"Suppl 12B","key":"10.1016\/j.breast.2026.104812_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.amjmed.2005.09.046","article-title":"Hot flashes: behavioral treatments, mechanisms, and relation to sleep","volume":"118","author":"Freedman","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.breast.2026.104812_bib22","doi-asserted-by":"crossref","first-page":"8466","DOI":"10.1038\/srep08466","article-title":"Neurokinin B administration induces hot flushes in women","volume":"5","author":"Jayasena","year":"2015","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.breast.2026.104812_bib23","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/GME.0000000000001090","article-title":"Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action","volume":"25","author":"Prague","year":"2018","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.breast.2026.104812_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13543784.2024.2305122","article-title":"Elinzanetant: a phase III therapy for postmenopausal patients with vasomotor symptoms","volume":"33","author":"Sassarini","year":"2024","journal-title":"Expert Opin Invest Drugs"},{"issue":"7","key":"10.1016\/j.breast.2026.104812_bib25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/14656566.2024.2358131","article-title":"Elinzanetant, a new combined neurokinin-1\/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms","volume":"25","author":"Hager","year":"2024","journal-title":"Expert Opin Pharmacother"},{"issue":"16","key":"10.1016\/j.breast.2026.104812_bib27","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/jama.2024.14618","article-title":"Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials","volume":"332","author":"Pinkerton","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.breast.2026.104812_bib28","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamainternmed.2025.4421","article-title":"Elinzanetant for the treatment of vasomotor symptoms associated with menopause: a phase 3 randomized clinical trial","volume":"185","author":"Panay","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"10382","key":"10.1016\/j.breast.2026.104812_bib32","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","article-title":"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study","volume":"401","author":"Lederman","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.breast.2026.104812_bib33","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1210\/clinem\/dgad058","article-title":"Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT","volume":"108","author":"Johnson","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.breast.2026.104812_bib34","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/AOG.0000000000005114","article-title":"Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial","volume":"141","author":"Neal-Perry","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.breast.2026.104812_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/03000605241247684","article-title":"Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I)","volume":"52","author":"Ruan","year":"2024","journal-title":"J Int Med Res"},{"issue":"5","key":"10.1016\/j.breast.2026.104812_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/03000605241246624","article-title":"Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial","volume":"52","author":"Yu","year":"2024","journal-title":"J Int Med Res"},{"key":"10.1016\/j.breast.2026.104812_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-079525","article-title":"Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial","volume":"387","author":"Schaudig","year":"2024","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.breast.2026.104812_bib29","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa2415566","article-title":"Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer","volume":"393","author":"Cardoso","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.breast.2026.104812_bib30","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/13543784.2021.1893305","article-title":"Fezolinetant in the treatment of vasomotor symptoms associated with menopause","volume":"30","author":"Depypere","year":"2021","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.breast.2026.104812_bib38","unstructured":"Astellas initiates phase 3 clinical study of fezolinetant for VMS in women with breast cancer receiving adjuvant endocrine therapy.."},{"issue":"S3","key":"10.1016\/j.breast.2026.104812_bib39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/cncr.23192","article-title":"Pharmacogenomics of tamoxifen and aromatase inhibitors","volume":"112","author":"Ingle","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.breast.2026.104812_bib40","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(11)70364-3","article-title":"Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial","volume":"13","author":"Mann","year":"2012","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.breast.2026.104812_bib41","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.2015.60.9412","article-title":"Electroacupuncture versus gabapentin for hot flashes among breast cancer survivors: a randomized placebo-controlled trial","volume":"33","author":"Mao","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104812_bib42","article-title":"Advances in the management of menopausal symptoms, fertility preservation, and bone health for women with breast cancer on endocrine therapy","volume":"43","author":"Lambertini","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"10.1016\/j.breast.2026.104812_bib43","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.6004\/jnccn.2010.0086","article-title":"Nonhormonal management of hot flashes for women on risk reduction therapy","volume":"8","author":"Sideras","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.breast.2026.104812_bib44","doi-asserted-by":"crossref","unstructured":"Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010 Sept 20;28(27):4120\u20134128..","DOI":"10.1200\/JCO.2009.25.9655"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:32:19Z","timestamp":1784928739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":41,"alternative-id":["S0960977626001220"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104812","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurokinin pathway antagonists for vasomotor symptoms in women with breast cancer: focus on elinzanetant and fezolinetant","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104812","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104812"}}